These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

688 related articles for article (PubMed ID: 19621692)

  • 1. The frequency of sister chromatid exchanges in patients with Crohn's disease and the effect of therapy with "anti-tumor necrosis factor" on this frequency.
    Danalioglu A
    Hepatogastroenterology; 2009; 56(91-92):729-33. PubMed ID: 19621692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
    Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
    Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
    Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
    Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
    Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased sister chromatid exchanges in peripheral lymphocytes of patients with Crohn's disease.
    Kang MH; Genser D; Elmadfa I
    Mutat Res; 1997 Nov; 381(1):141-8. PubMed ID: 9403040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
    Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G
    Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Infliximab therapy in children and adolescents with refractory Crohn's disease in the Netherlands; experience with 23 patients].
    de Ridder L; Escher JC; Taminiau JA
    Ned Tijdschr Geneeskd; 2002 Oct; 146(40):1879-83. PubMed ID: 12395595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
    Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study.
    Ryan BM; Russel MG; Schurgers L; Wichers M; Sijbrandij J; Stockbrugger RW; Schoon E
    Aliment Pharmacol Ther; 2004 Oct; 20(8):851-7. PubMed ID: 15479356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of sister chromatid exchanges and micronuclei monitored over time in patients with early-stage breast cancer: results of an observational study.
    Aristei C; Stracci F; Guerrieri P; Anselmo P; Armellini R; Rulli A; Barberini F; Latini P; Menghini AR
    Cancer Genet Cytogenet; 2009 Jul; 192(1):24-9. PubMed ID: 19480933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.
    Persoons P; Vermeire S; Demyttenaere K; Fischler B; Vandenberghe J; Van Oudenhove L; Pierik M; Hlavaty T; Van Assche G; Noman M; Rutgeerts P
    Aliment Pharmacol Ther; 2005 Jul; 22(2):101-10. PubMed ID: 16011668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey.
    Matsumoto T; Iida M; Motoya S; Haruma K; Suzuki Y; Kobayashi K; Ito H; Miyata M; Kusunoki M; Chiba T; Yamamoto S; Hibi T
    Dis Colon Rectum; 2008 Jun; 51(6):916-23. PubMed ID: 18322754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneous and gamma-ray-induced sister chromatid exchanges in patients with carcinoma of cervix uteri.
    Bozsakyová E; Wsólová L; Chalupa I
    Int J Radiat Biol; 2005 Feb; 81(2):177-85. PubMed ID: 16019927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn's colitis in response to infliximab treatment.
    Ljung T; Axelsson LG; Herulf M; Lundberg JO; Hellström PM
    Aliment Pharmacol Ther; 2007 Apr; 25(8):925-32. PubMed ID: 17402996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease.
    Franchimont N; Putzeys V; Collette J; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Franchimont D; Fiasse R; Pelckmans P; Malaise M; Belaiche J; Louis E
    Aliment Pharmacol Ther; 2004 Sep; 20(6):607-14. PubMed ID: 15352908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease.
    Eivindson M; Grønbaek H; Skogstrand K; Thorsen P; Frystyk J; Flyvbjerg A; Dahlerup JF
    Scand J Gastroenterol; 2007 Apr; 42(4):464-70. PubMed ID: 17454856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD19+ in intestinal mucosa predict the response to infliximab in Crohn's disease.
    Ferkolj I; Ihan A; Markovic S
    Hepatogastroenterology; 2005; 52(64):1128-33. PubMed ID: 16001645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.